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Background: Graves disease (GD) is an organ-specific autoimmune disease characterized by hyperthyroidism,
diffuse goiter, autoantibodies against thyroid-specific antigens, and dermopathy. Studies of GD have demonstrated
the importance of the Th2 and Th17 immune responses in mediating disease progression. In the present study, we
investigated the role of a Th2 cytokine, thymic stromal lymphopoietin (TSLP), in GD and Th17 differentiation.
Methods: In this study, we genotyped 470 patients with GD at 3 single nucleotide polymorphisms (SNPs) in TSLP.
In addition, the serum concentrations of TSLP were determined in 432 patients and 272 controls. Ten patients and
controls each were further screened using in vitro Th17 differentiation assays. The SNPs were genotyped using ABI
TaqManW SNP genotyping assays. For the Th17 differentiation assays, peripheral blood mononuclear cells (PBMCs)
isolated from the patients and controls were placed into Th17 differentiation media, and interleukin 17 expression
levels were determined.
Results: Haplotype analysis indicated that patients with the Ht3 (TCC) haplotype have a 3.28-fold higher risk of
developing GD (p = 0.007), whereas those with the Ht5 (TCG) haplotype had a 0.03-fold, reduced risk of developing
GD (p = 1 × 10−14). SNP rs3806933 (p = 0.007) was associated with female Graves ophthalmopathy (GO). TSLP
expression levels were higher in GD patients than in control subjects, and TLSP was also shown to promote the
differentiation of Th17 cells in GD patients.
Conclusions: These results suggest that polymorphisms in TSLP may be used as genetic markers for the diagnosis
and prognosis of GD. Furthermore, TLSP may be a target for treating GD.
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Graves’ disease (GD) is a complex, organ-specific auto-
immune disease characterized by a variety of clinical fea-
tures, such as hyperthyroidism, diffuse goiter, the presence
of autoantibodies against thyroid-specific antigens, and
dermopathy. The dysregulation of Th1 and Th2 responses
in patients with GD are associated with progression of the
disease. GD patients often present with anti-thyrotropin
receptor antibodies (TRAb)—an immune response regu-
lated by Th2 cells—which stimulate a variety of biological
responses that lead to hyperthyroidism and goiter [1].* Correspondence: leiwan@mail.cmu.edu.tw
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reproduction in any medium, provided the orMoreover, the recurrence of GD after treatment with
antithyroid drugs increases serum immunoglobulin E and
interleukin 13 (IL-13) levels, which are typical features of
a Th2 immune response [1].
Thymic stromal lymphopoietin (TSLP) is a member of
the hematopoietic cytokine family and is produced by
epithelial cells, keratinocytes, and granulocytes. Several
cellular targets of TSLP have been identified, including
dendritic cells, lymphocytes, and granulocytes. TSLP-
stimulated dendritic cells are able to activate CD4+ T cells
in an antigen-specific manner, resulting in T cells with the
Th2 phenotype that produce proallergic cytokines (IL-4,
IL-5, IL-13, and TNF-α), while down-regulating IL-10 and
IFN-γ [2]. Studies of TSLP in humans have indicated its
potential role in the Th2 inflammatory response. TSLP is. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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potential therapeutic target for the treatment of allergic
diseases [3,4]. Recent human studies have shown that
IL-17 is expressed in the airways of patients with asthma
and that IL-17 expression is greater in patients with mod-
erate to severe asthma compared with patients with mild
asthma and healthy subjects. TSLP and toll-like receptor
(TLR) 3 ligands activate CD11+ dendritic cells in human
blood to produce IL-23 and program naive CD4+ T cells
to differentiate into Th17 cells. TSLP-mediated Th17 cell
commitment under Th2-polarizing conditions may be
involved in the development of an inflammatory mixture
of Th2 and Th17 cells, a unique profile that resembles se-
vere asthma [5]. The proportion of Th17 cells in GD
patients is higher than that in control subjects [6,7]. Th17
cells thus play an important role in GD and other inflam-
matory autoimmune disorders, including multiple sclerosis
[8,9], rheumatoid arthritis [10,11], and Crohn’s disease
[12]. In rheumatoid arthritis (RA) patients, the expression
levels of TSLP and IL-17 are increased in the synovial fluid.
TSLP was shown to promote Th17 differentiation and
enhance arthritis in murine rheumatoid arthritis models,
indicating the importance of TSLP in the differentiation of
Th17 and the involvement of TSLP in the pathogenesis of
autoimmune disease [13].
The role of TSLP in Th17 cell differentiation impli-
cates TSLP in the pathogenesis of GD. However, TSLP
has not been directly investigated in the context of GD;
its role in the disorder thus remains unclear. In the
present study, we indicated that TSLP polymorphisms
are associated with GD and that expression levels of
TSLP are higher in patients than in control subjects. In
addition, we showed that TSLP mediates the differenti-
ation of CD4+ T cells into Th17 cells.
Methods
Patients
A total of 470 patients with GD were enrolled in this study.
The diagnosis of GD was performed by endocrinologists
and Graves’ ophthalmopathy (GO) was assessed by
ophthalmologists. The diagnosis of GD was made on the
basis of clinical symptoms and biochemical affirmation of
hyperthyroidism, multinodular goiter, and a positive result
for at least one of the following biochemical tests: thyroid-
stimulating hormone receptor antibody, diffusely increased
iodine-131 uptake in the thyroid gland, and exophthalmos.
Patients with GD were classified in accordance with the
NOSPECS system recommended by the American Thyroid
Association. In GD patients, GO was identified by prop-
tosis, with or without a more severe phenotype (classes
3–6). Proptosis was measured by a Hertel exophthalm-
ometer and was defined as the anteroposterior protrusion
of the globe by more than 19 mm from the lateral orbital
rim in either eye, or by any discrepancy in the degree ofprotrusion of the 2 eyes of more than 1 mm. The demo-
graphic and clinical characteristics of control subjects and
Graves’ disease patients are listed in Additional file 1: Table
S1. We selected gender- and age-matched controls for the
association study, the functional assay and the in vitro
IL-17 differentiation experiments. The patient and control
groups of in vitro IL-17 differentiation experiment each
comprised 2 male and 8 female individuals, and both
groups had mean ages of 38.42 ± 10.91 and 40.12 ±
8.48 years, respectively. Blood samples were collected for
genomic DNA isolation and serological tests. This study
was approved by the ethical committee and institutional
review board of the China Medical University Hospital.
Informed consent was obtained from all patients or their
guardians.
SNP genotyping and ELISA
TSLP SNP genotype information was retrieved from the
HapMap database for the HCB + JPT populations. Tag-
ging SNPs were selected through the Tagger function in
the Haploview software program. The selection criteria
were: (1) the minor allele frequency should be greater
than 10%; (2) SNPs that potentially affect transcription
efficiency, translation efficacy, or protein functions were
selected first; and (3) the availability of probes or pri-
mers that pass the manufacturer’s qualification require-
ments (Applied Biosystems Inc., Foster City, CA). Only
the following 4 SNPs fulfilled the criteria: rs3806933,
rs2289276, rs2289278, and rs11466741. The rs3806933
and rs2289276 SNPs are located in the promoter region
and rs2289278 is located in intron 2. Genotyping
rs3806933, rs2289276, and rs2289278 captured 4 of 4
(100%) alleles with r2 ≥ 0.8. SNPs were genotyped using
ABI TaqManW SNP genotyping assays (rs3806933:
C_3166722_10; rs2289276: C_3166723_20; rs2289278:
C_15880989_10; Applied Biosystems) on a Roche Light-
CyclerW480 system (Roche). Haplotypes were inferred
from unphased genotype data using the Bayesian statis-
tical method in the Phase 2.1 software program. All 3
SNPs were analyzed using Phase 2.1 software. TSLP
concentrations in sera were determined with ELISA kits
(eBioscience Inc.).
Th17 differentiation assay
Peripheral blood mononuclear cells (PBMC) were isolated
from 10 healthy individuals (5 male and 5 female subjects)
and 10 Graves’ disease patients (5 male and 5 female
patients), and cultured in RPMI1640 medium containing
10% fetal bovine serum. Stimulation was performed
with plate-bound anti-CD3 and anti-CD28 (1 μg/mL and
1 μg/mL, respectively). A total of 1.2 × 104 PBMC were
plated into each well of a round-bottom 96-well plate.
The media contained 10 ng/mL of TGF-β, 10 ng/mL of
IL-23, 10 ng/mL of IL-6, 10 ng/mL of IL-1β, 1 μg/mL of
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TSLP, and incubated at 37°C with 5% CO2 for 5 days. IL-17
concentrations were determined by ELISA.
Statistical analysis
IBM SPSS statistics software version 20.0 (IBM Corpor-
ation) was used to analyze the data. The genotype fre-
quency and allelic frequency distributions of the
polymorphisms in patients with GD (with or without
GO) were analyzed by the chi-square method. The dif-
ference in sera TSLP concentrations between control
subjects and patients was analyzed by t-test. A p-value
less than 0.05 was considered statistically significant.
The odds ratio (OR) was calculated from genotype fre-
quencies and allelic frequencies with a 95% confidence
interval (CI).
Results
To investigate potential associations between TSLP and
GD, 3 polymorphisms in the TSLP gene were selected for
this study. A total of 470 patients and 78 control subjects
were genotyped at these SNPs. Genotype frequencies from
our GD cohort were then compared with those of the nor-
mal healthy population. The rs2289276 SNP was found to
be associated with GD when compared with the general
population (recessive model, p = 0.027; Table 1). Statistical
significance was lost when adjusted for multiple compari-
sons (Bonferroni correction; p < 0.016). Haplotype analysis
indicated that patients with the Ht3 (TCC) haplotype
have a 3.28-fold higher risk of developing GD (p = 0.007),
whereas those with the Ht5 (TCG) haplotype had a
0.03-fold reduced risk of developing GD (p = 1 × 10−14)
(Table 2). We then grouped the GD patients on the basis
of the presence or absence of GO to determine whether
TSLP polymorphisms were associated with the GO pheno-
type. The rs3806933 SNP was found to be associated with
GO under a genotypic model (p = 0.028). Using a domin-
ant model comparison, rs3806933 (p = 0.021; OR, 1.54;
95% CI: 1.07, 2.23) and rs2289278 (p = 0.045; OR, 1.47;
95% CI: 1.01, 2.14) were both associated with GO
when compared with patients without GO. In addition,
rs2289276 was associated with GO under a recessive
model (p = 0.026; OR, 2.98; 95% CI: 1.09, 8.12; Table 1).
Statistical significance was lost when adjusted for mul-
tiple comparisons (Bonferroni correction; p < 0.016).
Both rs2289276 and rs3806933, which are located in
the promoter region of TSLP, are known to influence
TSLP expression [14]. However, no significant differ-
ences in allele frequencies were observed between
patients with GO and those without GO or between
patients with GO and the normal population (Table 1).
In this study, there were 374 female and 96 male
patients. Given that 79.6% of the patients were female,
a sex-stratified analysis was used to identify possibleassociations with TSLP polymorphisms. Table 3 shows
significant differences in TLSP alleles between patients
with GO and those without GO. Under a dominant
model, we observed 1.52- and 1.7-fold increases in the
risk of developing GO in female GD patients for particu-
lar genotypes at rs3806933 and rs2289278, respectively.
For the C/T and C/C genotypes at rs2289276, we
observed 6- and 4.93-fold increases in the risk of devel-
oping GO in female GD patients, respectively. Signifi-
cant differences in TSLP genotype and allele frequencies
were not observed in male GD patients (Table 3). Fe-
male GD patients harboring the G allele at rs2289278
were found to have a 1.56-fold increased risk for GO
(Table 3).
Serum TSLP concentrations were determined in 272
control individuals, 184 GD patients with GO, and 248
GD patients without GO. The TSLP concentrations
were significantly lower in the control subjects (p <
0.00001; Table 4). No significant differences were
observed in TSLP expression levels between male and
female patients or between patients with and without
GO. Treating PBMC from control subjects and GD
patients in vitro with higher TSLP concentrations
increased IL-17 expression under conditions of Th17
differentiation. In the presence of IL-23, IL-6, IL-1β,
TGF-β, TSLP, anti–IL-4, and anti–IFN-γ, the IL-17
expression levels increased with the TSLP concentra-
tion (Figure 1).
Discussion
In this study, we demonstrated that TSLP polymorphisms
are associated with GD and with GO in female GD
patients, and that TSLP concentrations are increased in
GD patients. We found an association between TSLP hap-
lotypes and GD. Ht3 is a risk haplotype for GD, whereas
Ht5 is a protective haplotype. No significant associations
were observed between GD with GO and GD without GO
before gender stratification. rs3806933, rs2289276, and
rs2289278 showed significant associations with the pres-
ence or absence of GO in GD in female patients but not
in male patients. This may be a result of the small number
of male patients in our cohort. Increased expression TSLP
levels induced CD4+ T cells to differentiate into Th17
cells, which are key players in GD development. IL-17 has
a regulatory role in neutrophil recruitment and regulates
the expression of inflammatory cytokines in epithelial
cells, resulting in the induction of inflammation. The dys-
regulation of IL-17 production leads to chronic inflamma-
tion and tissue damage, both of which may lead to the
development of GD.
The differentiation of Th17 cells is mediated by the
combinatorial effects of TSLP, IL-23, TNF-α, TGF-β, IL-6,
and IL-1β, which promote the expression of IL-17 [15]. In
addition to TSLP polymorphisms, polymorphisms in the
Table 1 Genotype and allele frequencies of markers for Graves’ disease patients in Taiwan
SNP ID GD with GO (201) GD without GO (269) GD (470) Control (78) P a P b OR (95% CI)
N (%) N (%) N (%) N (%)
Genotype
rs3806933
C/C 83(41.3) 140 (52.0) 223 (47.4) 37 (47.4) 1
C/T 101 (50.2) 102 (37.9) 203 (43.2) 31 (39.7) 1.67 (1.13, 2.46)
T/T 17 (8.5) 27 (10.0) 44 (9.4) 10 (12.9) 0.028 (genotype) 0.61 1.06 (0.55, 2.06)
C/T + T/T 118 (58.7) 129 (48.0) 247 (52.6) 41 (52.6) 0.021 (dominant) 1 1.54 (1.07, 2.23)
rs2289276
C/C 5 (2.5) 19 (7.1) 24 (5.1) 9 (11.5) 1
C/T 77 (38.3) 90 (33.5) 167 (35.5) 29 (37.2) 3.25 (1.16, 9.12)
T/T 119 (59.2) 160 (59.5) 279 (59.4) 40 (51.3) 0.065 (genotype) 0.067 2.83 (1.03, 7.79)
C/T + C/C 196 (97.5) 250 (92.9) 446 (94.9) 69 (88.5) 0.026 (recessive) 0.027 2.98 (1.09, 8.12)
rs2289278
C/C 114 (56.7) 177 (65.8) 291 (61.9) 41 (52.6) 1
C/G 73 (36.3) 79 (29.4) 152 (32.3) 32 (41.0) 1.43 (0.97, 2.13)
G/G 14 (14) 13 (4.8) 27 (5.8) 5 (6.4) 0.125 (genotype) 0.29 1.67 (0.76, 3.69)
C/G + G/G 87 (50.3) 92 (34.2) 179 (38.1) 37 (47.4) 0.045 (dominant) 0.12 1.47 (1.01, 2.14)
Allele
rs3806933
C allele 267 (66.4) 382(71.0) 649 (69) 105 (67.3) 1
T allele 135 (33.6) 156 (29.0) 291 (31) 51 (32.7) 0.13 0.66 1.24 (0.94, 1.64)
rs2289276
T allele 315 (78.4) 410 (76.2) 725 (77.1) 109 (69.9) 1
C allele 87 (21.6) 128 (23.8) 215 (22.9) 47 (30.1) 0.44 0.05 0.88 (0.65, 1.21)
rs2289278
C allele 301 (74.9) 433 (80.5) 734 (78.1) 114 (73.1) 1
G allele 101 (25.1) 105 (19.5) 206 (21.9) 42 (26.9) 0.04 0.17 1.38 (1.01, 1.89)
Abbreviations: CI, confidence interval; GO, Graves’ ophthalmopathy; SNP, single-nucleotide polymorphism. aDifferences in allele, dominant or recessive genotype
frequencies were determined by chi-square test using 2 × 2 contingency tables. Differences in genotype frequencies were determined by chi-square test using
2 × 3 contingency tables. Compared Graves’ diseases patients with and without GO. b Compared Graves’ disease patients with normal population. P values less
than 0.016 were considered significant.
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and +915G/C) [17], IL-6 (+572G) [18], TNF-α (+1031C)
[19], and 1 SNP in IL-1β (rs1143634) [20] were found to
be associated with GD. Moreover, the serum expression
levels of IL-6, IL-1β, and TNF-α were higher in GD patients
compared with control subjects [21]. The increased expre-Table 2 The association between TSLP gene haplotypes amon
Haplotype* rs3806933 rs2289276 rs2289278
Ht1 C C C
Ht2 C C G
Ht3 T C C
Ht4 T T C
Ht5 T C G
* The haplotypes were identified by the Bayesian statistical method available in the
** The chi-square test (2 × 2 table) was performed to obtain the p value. For examp
the numbers of control and GD without Ht1. A p value < 0.01 was considered as sta
cases or controls are shown.ssion of these proteins is believed to promote Th17 differ-
entiation. These cytokines and chemokines are normally
under strict control and do not produce disease symptoms
under normal circumstances. However, some individuals
are likely predisposed to cytokine or chemokine-mediated
disease because of their genetic background. Individualsg control and GD patients
Control GD p value** OR (95% CI)
60 433 0.09 1.35 (0.95–1.9)
37 205 0.56 0.89 (0.59–1.32)
5 93 0.007 3.28 (1.31–8.21)
39 200 0.27 0.8 (0.54–1.19)
12 2 1 × 10−14 0.03 (0.01–0.11)
program Phase 2.1.
le, the numbers of haplotypes of control and GD with Ht1 were compared with
tistically significant. Only haplotype with a frequency of 0.01 or above in either
Table 3 The genotype frequency of stratified by gender
among Graves’ disease patients in Taiwan
SNP ID with GO w/o GO P valuea OR (95% CI)
N (%) N (%)
rs3806933
Female
C/C 64 (42.7) 119 (53.1) 1
C/T 77 (51.3) 80 (35.7) 1.79 (1.16, 2.77)
T/T 9 (6) 25 (11.2) 0.007 (genotype) 0.67 (0.29, 1.52)
C/T + T/T 86 (57.3) 105 (46.9) 0.047 (dominant) 1.52 (1.00, 2.31)
C allele 205 (68.3) 318 (71.0) 1
T allele 95 (31.7) 130 (29.0) 0.44 1.13 (0.83, 1.56)
Male
C/C 19 (37.3) 21 (46.7) 1
C/T 24 (47.1) 22 (48.9) 1.21 (0.52, 2.82)
T/T 8 (15.7) 2 (4.4) 0.18 (genotype) 4.42 (0.83, 23.47)
C/T + T/T 32 (62.7) 24 (53.3) 0.35 (dominant) 1.47 (0.65, 3.33)
C allele 62 (60.8) 64 (71.1) 1
T allele 40 (39.2) 26 (28.9) 0.13 1.59 (0.87, 2.91)
rs2289276
Female
T/T 2 (1.3) 15 (6.7) 1
C/T 60 (40.0) 75 (33.5) 6.00 (1.32, 27.27)
C/C 88 (58.7) 134 (59.8) 0.034 (genotype) 4.93 (1.10, 22.07)
C/T + C/C 148 (98.7) 209 (93.3) 0.015 (recessive) 5.31 (1.20, 23.57)
C allele 236 (78.7) 343 (76.6) 1
T allele 64 (21.3) 105 (23.4) 0.50 0.89 (0.62, 1.26)
Male
T/T 3 (5.9) 4 (8.9) 1
C/T 17 (33.3) 15 (33.3) 1.51 (0.29, 7.87)
C/C 31 (60.8) 26 (57.8) 0.847 (genotype) 1.59 (0.33, 7.76)
C/T + C/C 48 (94.1) 41 (91.1) 0.572 (recessive) 1.56 (0.33, 7.38)
C allele 79 (77.5) 67 (74.4) 1
T allele 23 (22.5) 23 (25.6) 0.63 0.85 (0.44, 1.65)
rs2289278
Female
C/C 80 (53.3) 148 (66.1) 1
C/G 59 (39.3) 66 (29.5) 1.65 (1.06, 2.58)
G/G 11 (7.3) 10 (4.5) 0.042 (genotype) 2.04 (0.83, 5.00)
C/G + G/G 70 (46.7) 76 (33.9) 0.013 (dominant) 1.70 (1.12, 2.60)
C allele 219 (73.0) 362 (80.8) 1
G allele 81 (27.0) 86 (19.2) 0.012 1.56 (1.10, 2.20)
Male
C/C 34 (66.7) 29 (64.4) 1
C/G 14 (27.5) 13 (28.9) 0.92 (0.37, 2.27)
G/G 3 (5.9) 3 (6.7) 0.971 (genotype) 0.85 (0.16, 4.55)
Table 3 The genotype frequency of stratified by gender
among Graves’ disease patients in Taiwan (Continued)
C/G + G/G 17 (33.3) 16 (35.6) 0.819 (dominant) 0.91 (0.39, 2.11)
C allele 82 (80.4) 71 (78.9) 1
G allele 20 (19.6) 19 (21.1) 0.80 0.91 (0.45, 1.84)
Abbreviations: CI, confidence interval; GO, Graves’ ophthalmopathy; SNP,
single-nucleotide polymorphism. aDominant or recessive genotype frequencies
were determined by chi-square test using 2 × 2 contingency tables. Genotype
frequencies were determined by chi-square test using 2 × 3 contingency
tables. Compared Graves’ diseases patients with and without GO. P values less
than 0.016 were considered significant.
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quantities of TSLP, IL-6, IL-1β, and TNF-α and therefore,
greater numbers of Th17 cells in the presence of appropri-
ate stimuli. This genetic tendency may be regulated by
polymorphisms in TSLP, IL-23, TGF-β, IL-6, IL-1β, and
TNF-α.
We found that TSLP polymorphisms were only asso-
ciated with GO in female patients. Approximately 78% of
individuals with autoimmune disease are women. Women
have increased antibody production (Th2 response) in re-
sponse to infection or vaccination. In GD, the production
of autoantibodies against thyrotropin receptor stimulates
thyroid cells and contributes to the onset of the disease.
Estrogen has been shown to increase Th2 response,
whereas androgen increases Th1 response; this hormone-
mediated difference may account for the higher number
of female patients with GD. Given that only 96 male GD
patients were included in this study, it is difficult to con-
clusively exclude a role for TSLP polymorphisms in the
development of GD or GO in male patients.Table 4 Serum concentration of TSLP in control and
Graves’ disease patients
Samples No. TSLP concentration (pg/ml) Pa Pb
Control 272 15.46 ± 35.25
GD 432 109.93 ± 189.13 < 0.00001
GD/GO 184 113.43 ± 221.44 < 0.00001
GD/w/o GO 248 107.33 ± 161.47 < 0.00001 0.75
Female
Control 166 17.90 ± 29.69
GD 343 111.70 ± 189.30 < 0.00001
GD/GO 138 114.55 ± 216.48 < 0.00001
GD/w/o GO 205 109.77 ± 169.10 < 0.00001 0.83
Male
Control 106 11.64 ± 43.96
GD 89 103.11 ± 189.38 < 0.00001
GD/GO 46 110.06 ± 238.15 < 0.00001
GD/w/o GO 43 95.68 ± 119.46 < 0.00001 0.72
aP values were determined by unpaired T test to compare between control
and GD, GD/GO, GD/w/o GO. bP values were determined by unpaired T test to
compare between GD/GO and GD/w/o GO. P values less than 0.05 were
considered significant.
Figure 1 TSLP increased Th17 differentiation in human PBMC
isolated from 10 control subjects and 10 GD patients. PBMC
were activated by anti-CD3 and anti-CD28. Th17 differentiation was
promoted by adding 10 ng/mL of TGF-β, 10 ng/mL of IL-23, 10 ng/mL
of IL-6, 10 ng/mL of IL-1β, and 1 μg/mL of anti-IL4 and anti-IFNγ with
(C-TSLP or P-TSLP), or without (C or P)125 ng/mL of TSLP. The
concentrations of IL-17 in the culture supernatants were determined
by enzyme-linked immunosorbent assay. C: control; P: patient. Values
are mean ± standard deviation of 3 independent measurements.
Student’s t tests have produced p values for the paired comparisons
C versus P, C-TSLP versus P-TSLP, and P versus P-TSLP of 0.0381, 0.0027,
and 0.0277, respectively.
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the importance of TSLP in GD, particularly focusing on
male GD patients. Ultimately, more clearly defining the
roles of cytokine networks in the onset and pathogenesis
of GD will aid the development of novel therapeutic
regimens and treatment for patients who do not respond
to existing therapies.Conclusions
The results obtained in this study suggest that the TSLP
gene may be a relevant candidate gene for susceptibility
to GD. TSLP genotypes may be used as genetic markers
for the diagnosis and prognosis of GD. Furthermore,
TLSP may be a target for treating GD.Additional file
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